Skip to content
ReframedNewsLeft · Right · Centered
Quick ReadArchiveAboutSign in
Briefing stories›Business & Markets

Novo Nordisk Shares Fall After Ziltivekimab Misses Primary Goal in Phase 3 ZEUS Heart Trial

Story date · Friday, July 31, 2026Business & MarketsWell-covered

The facts

  • Novo Nordisk announced on July 31, 2026 that ziltivekimab did not reduce major adverse cardiovascular events versus placebo in the Phase 3 ZEUS trial, with a hazard ratio of 0.99 (95% confidence interval 0.88 to 1.11).
  • ZEUS was a double-blind, placebo-controlled trial enrolling more than 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation defined as hsCRP of at least 2 mg/L, testing once-monthly subcutaneous ziltivekimab 15 mg.
  • The drug did engage its intended target, producing the expected reductions in free IL-6 and high-sensitivity C-reactive protein, but this did not translate into fewer cardiovascular deaths, non-fatal heart attacks or non-fatal strokes.
  • Novo Nordisk's shares fell on the announcement, dropping roughly 7% to 10% on the Copenhagen listing and about 9% to 10% for the U.S.-listed shares in premarket and early trading.
  • Novo Nordisk said the trial result does not change its adjusted operating profit outlook for 2026, but that it will lead to a non-cash impairment charge in the third quarter.
  • Two additional late-stage ziltivekimab trials — HERMES in heart failure and ARTEMIS in people who have had an acute heart attack — will continue, with results expected in the first half of 2027.
  • Analysts had expected ziltivekimab to become a multibillion-dollar product that would help diversify Novo Nordisk's portfolio beyond its obesity and diabetes franchise; TD Cowen called the outcome a surprise and a major setback, and JPMorgan's Richard Vosser said the failure costs the company a multibillion-euro asset.
  • Chief scientific officer Martin Holst Lange said the result was disappointing and that ZEUS had been designed to test whether IL-6 inhibition would convert reductions in cardiovascular inflammation into fewer cardiovascular events; the company said it remains committed to cardiovascular disease.
  • The outcome raises questions about the broader strategy of targeting inflammation to prevent cardiovascular complications, and full ZEUS results are to be presented at an upcoming scientific meeting.

Context

What is ziltivekimab and what was ZEUS testing?

Ziltivekimab is a monoclonal antibody given as a once-monthly injection that targets the IL-6 ligand, a protein involved in chronic inflammation and the liver's release of C-reactive protein Superhits 97.9 Terr…,Motley Fool. ZEUS was designed to test whether blocking the IL-6 pathway could turn reductions in cardiovascular inflammation into fewer major cardiovascular events — defined as cardiovascular death, non-fatal heart attack or non-fatal stroke — in patients with atherosclerotic cardiovascular disease, chronic kidney disease and elevated hsCRP wallstreet:online,Manila times,cnbctv18.com.

Why does this matter beyond Novo Nordisk?

Because ziltivekimab lowered inflammatory markers without reducing cardiovascular events, investors and analysts treated the result as a test of the wider hypothesis that reducing cardiovascular inflammation prevents heart attacks and strokes STAT,Healio. Shares of other companies developing anti-inflammatory cardiovascular drugs fell sharply the same day, including BioAge Labs, whose lead oral NLRP3 inhibitor is in a Phase 2 trial, and Monte Rosa Therapeutics, which works in adjacent inflammatory pathways Investing.com,Investing.com.

What happens to the ziltivekimab program now?

Novo Nordisk said it will continue the two other ongoing late-stage trials, HERMES in heart failure and ARTEMIS in patients following an acute heart attack, with data expected in the first half of 2027 Morningstar,wallstreet:online,Motley Fool. Reporting notes that some analysts are skeptical those trials can salvage the program after the ZEUS miss FierceBiotech - fre….

Were there safety concerns in the trial?

Novo Nordisk said overall rates of adverse events were similar between patients who received ziltivekimab and those who received placebo Morningstar,Yahoo! Finance. The company described the announcement as headline results, with full data to be presented at a scientific meeting Manila times,Healio.

Common ground, and where they split

Common ground
A drug that hit its biomarker targets exactly as designed still prevented no deaths, heart attacks or strokes — and both reads treat the honest disclosure of that null result as the valuable part.
Where Left and Right split
Hard outcome trials proving that lowered inflammation markers are not patient benefit, or a market and a company absorbing a failed bet in hours without hiding it.

How left and right read it

Left says

More than 6,300 people with atherosclerotic heart disease and chronic kidney disease sat through a placebo-controlled trial that produced a hazard ratio of 0.99. The drug lowered IL-6 and hsCRP exactly as designed, and none of it prevented a single extra death, heart attack or stroke. That is the point of hard outcome trials. Biomarkers are not benefit, and patients — not the multibillion-euro asset analysts priced in — are what the evidence has to answer to.

Right says

Novo Nordisk announced on July 31, 2026 that ziltivekimab missed on major cardiovascular events, and shares repriced 7% to 10% in Copenhagen and roughly 9% to 10% in the U.S. within hours. That is a price signal doing its job. The company disclosed the miss, booked the non-cash impairment, held its 2026 profit outlook and kept HERMES and ARTEMIS running — honest accounting of a failed bet, which is precisely what should keep private risk capital funding the next one.

See this differently than someone you know would?

The receipts — 44 sources

Wire services (1)

ReutersSuperhits 97.9 Terre Haute, INNovo Nordisk's anti-inflammatory drug fails to reduce cardio...

Other coverage (43)

stock-world.deNovo Nordisk Aktie: Ziltivekimab verfehlt ZEUS-Endpunkt
조선일보Novo Nordisk Cardiovascular Drug Fails Phase 3, Stock Plumme...
Asianet News Network Pvt LtdNVO Stock Ends Three-Month Winning Streak As Novo Nordisk's ...
Yahoo! FinanceNVO Stock Ends Three-Month Winning Streak As Novo Nordisk's ...
Asianet News Network Pvt LtdBIOA, GLUE Stocks Clock Worst Day In Years -- What's The NVO...
Markets InsiderIs Novo Nordisk Stock (NVO) a Good Buy After Today's Plunge?
NASDAQ Stock MarketNovo Nordisk Shares Plunge After a Key Trial Fails. Should I...
Yahoo! FinanceNovo Nordisk Shares Plunge After a Key Trial Fails. Should I...
The Motley FoolNovo Nordisk Shares Plunge After a Key Trial Fails. Should I...
Barchart.comNVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Sta...
Tech TimesZiltivekimab Cuts Inflammation, Fails to Cut Heart Attacks: ...
Yahoo! FinanceWeight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below ...
YahooNovo Nordisk's mAb for MACE risk reduction fails in Phase II...
wallstreet:onlineNovo Nordisk mit Entwicklungsfehlschlag - Aktienkurs sackt a...
finanzen.chNovo Nordisk mit Entwicklungsfehlschlag - Aktienkurs sackt a...
Börse OnlineNovo Nordisk mit Entwicklungsfehlschlag - Aktienkurs sackt a...
Asianet News Network Pvt LtdNVO Stock Slumps After Late-Stage Trial Fails Primary Goal -...
Yahoo! FinanceNovo Nordisk Suffers Another Pipeline Setback
Yahoo! FinanceNovo Nordisk Stock Falls 7% as ZEUS Trial Fails
stock-world.deNovo Nordisk Aktie: 10-Prozent-Einbruch nach ZEUS-Flop
Investing.comWhy is BioAge Labs stock plunging 60% today? By Investing.co...
BlockonomiNovo Nordisk (NVO) Stock Tumbles 9% as ZEUS Trial Falls Shor...
Yahoo! FinanceNVO Stock Slumps After Late-Stage Trial Fails Primary Goal -...
Börse OnlineNächster Schock für Novo Nordisk-Aktionäre: Darum rauscht di...
RTTNewsNovo Nordisk's ZEUS Trial Shows No Cardiovascular Event Redu...
FierceBiotech - free daily biotech briefingNovo Nordisk left praying to Artemis and Hermes to salvage C...
InvestopediaNovo Nordisk Stock Sinks on Disappointing Heart Drug Trial R...
Financial Times NewsNovo Nordisk shares drop 10% after heart attack drug trial d...
QuartzNovo Nordisk ziltivekimab-Herzmedikament fällt im Phase-3-Ve...
QuartzNovo Nordisk ziltivekimab heart drug fails phase 3 trial
cnbctv18.comNovo Nordisk shares tumble after heart drug misses key late-...
The Wall Street JournalNovo Nordisk Stock Drops After Drug Fails in Cardiovascular ...
STATNovo Nordisk inflammation-targeting drug misses mark in hear...
Investing.comWhy is Monte Rosa Therapeutics stock plunging today? By Inve...
MorningstarNovo Nordisk Shares Drop After Drug Candidate Fails in Cardi...
Yahoo! FinanceNovo Nordisk stock tumbles 10% as key trial misses goal
Investing.comWhy is Novo Nordisk stock plunging today? By Investing.com
The Manila timesNovo Nordisk provides update on the ZEUS phase 3 trial in pe...
Investing.comNovo Nordisk stock tumbles 10% as key trial misses goal By I...
Taiwan NewsNovo Nordisk provides update on the ZEUS phase 3 trial in pe...
wallstreet:onlineNovo Nordisk provides update on the ZEUS phase 3 trial in pe...
HealioZiltivekimab reduces inflammation, not MACE risk in patients...
BioPharma DiveNovo setback casts doubt on a new way to treat heart disease

A news briefing built to show both sides.

The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.

A news briefing built to show both sides.

The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.

ReframedNews

A daily news briefing on the day’s top stories, built to show both sides.

Written by AI from news reporting. We review published briefings. Who writes this →

Navigate

Quick ReadArchiveSettings

Company

AboutHow it worksSkylark CreationsSign InTerms of ServicePrivacy Policy

© 2026 Reframed.News

Made by Skylark Creations